



3.3.5 Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

Publications: 18

Impact Factor: 79.⁶²

Q1: 7



Research Activity

Publications

- Amesty MV, Fernández C, Espinosa L, Rivas-Vila S, Lobato R, Monsalve S, López-Pereira PC, Martínez-Urrutia MJ. Long-term outcomes of adult-size and size-matched kidney transplants in small pediatric recipients. *J Pediatr Urol.* 2020; 16(4): 481.e1-8. Article. IF: 1,83; Q3
- Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Caverro T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juarez G, Rodríguez A, de José AP, Rabasco C, Rodado R, Fernández L, Gómez VP, Ávila AI, Bravo L, Lumbreras J, Allende N, de la Nieta MDS, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megias M, González F, Shabaka A, López-Rubio ME, Fenollosa MA, Martín-Penagos L, Da Silva I, Titos JA, de Cordoba SR, de Jorge EG, Praga M. Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. *Clin J Am Soc Nephrol.* 2020; 15(9): 1287-98. Article. IF: 8.237; D1
- Corvillo F, Ceccarini G, Nozal P, Magno S, Pelosini C, Garrido S, López-Lera A, Moraru M, Vilches C, Fornaciari S, Gabbrellini S, Santini F, Araujo-Vilar D, López-Trascasa M. Immunological features of patients affected by Barraquer-Simons syndrome. *Orphanet J Rare Dis.* 2020; 15(1): 9. Article. IF: 4.123; Q2
- Corvillo F, de la Morena-Barrio ME, Marcos-Bravo C, López-Trascasa M, Vicente V, Emsley J, Caballero T, Corral J, López-Lera A. The FXII c.-4T > C polymorphism as a disease modifier in patients with hereditary angioedema due to the FXII p.Thr328Lys variant. *Front Genet.* 2020; 11: 1033. Article. IF: 4.599; Q2
- Corvillo F, Nozal P, López-Lera A, de Miguel MP, Pinero-Fernández JA, de Lucas R, García-Concepción MD, Beato MJ, Araujo-Vilar D, López-Trascasa M. Evidence of ongoing complement activation on adipose tissue from an 11-year-old girl with Barraquer-Simons syndrome. *J Dermatol.* 2020; 47(12): 1439-44. Article. IF: 4.005; Q2
- Dezfouli M, Bergstrom S, Skattum L, Abolhasani H, Neiman M, Torabi-Rahvar M, Jarava CF, Martín-Nalda A, Balaguer JMF, Slade CA, Roos A, Pereira LMF, López-Trascasa M, González-Granado LI, Allende-Martínez LM, Mizuno Y, Yoshida Y, Friman V, Lundgren A, Aghamohammadi A, Rezaei N, Hernández-González M, von Döbeln U, Truedsson L, Hara T, Nonoyama S, Schwenk JM, Nilsson P, Hammarstrom L. Newborn screening for presymptomatic diagnosis of complement and phagocyte deficiencies. *Front Immunol.* 2020; 11: 455. Article. IF: 7.561; Q1
- Doménech N, Sánchez-Corral P. Xenoantibodies and complement activity determinations by flow cytometry in pig-to-primate xenotransplantation. *Methods Mol Biol.* 2020; 2110: 73-81. Article. Not Indexed
- Dona D, Canizales JT, Benetti E, Cananzi M, De Corti F, Calore E, Hierro L, Boluda ER, Hijosa MM, Guereta LG, Martínez AP, Barrios M, Reis PC, Teixeira A, Lopes MF, Kalicinski P, Branchereau S, Boyer O, Debray D, Sciveres M, Wennberg L, Fischler B, Barany P, Baker A, Baumann U, Schwerk N, Nicastro E, Candusso M, Toporski J, Sokal E, Stephenne X, Lindemans C, Miglinas M, Rascon J, Jara P. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. *Clin Transplant.* 2020;



- 34[10]: e14063. Article. IF: 2.863; Q2
- Germentis AE, Margaglione M, Pesquero JB, Farkas H, Cichon S, Csuka D, Lera AL, Rijavec M, Jolles S, Szilagyi A, Trascasa ML, Veronez CL, Drouet C, Zamanakou M. International consensus on the use of genetics in the management of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2020; 8(3): 901-11. Article. IF: 8.861; Q1
 - Gokmen NM, Rodríguez-Alcalde C, Gulbahar O, López-Trascasa M, Onay H, López-Lera A. Novel homozygous variants in the SERPING1 gene in two Turkish families with hereditary angioedema of recessive inheritance. *Immunol Cell Biol.* 2020; 98(8): 693-9. Article. IF: 5.126; Q2
 - López-Gálvez R, de la Morena-Barrio ME, López-Lera A, Pathak M, Minano A, Serrano M, Borgel D, Roldan V, Vicente V, Emsley J, Corral J. Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. *Orphanet J Rare Dis.* 2020; 15(1): 280. Article. IF: 4.123; Q2
 - Martínez Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, Nozal P, Angeles Gonzalez M, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A. Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. *Semin Arthritis Rheum.* 2020; 50(1):E1-2. Letter. IF: 5.532; Q1
 - Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Díez J, García-Ramírez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín- Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. *Sci Rep.* 2020; 10(1): 17099. Article. IF: 4.379; Q1
 - Medina PG, Román LE. Importance of assessing compliance with conservative treatment of pri-

- mary hyperoxaluria type 1: A case report of a patient with I244T/c.969-3C>G Mutation. *Perm J.* 2020; 24(19): 136. Article. Not Indexed
- Melgosa M, Madrid A, Álvarez O, Lumbreras J, Nieto F, Parada E, Pérez-Beltrán V. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. *Pediatr Nephrol.* 2020; 35(8): 1521-4. Article. IF: 3.714; Q1
 - Ponard D, Gaboriaud C, Charignon D, Ghannam A, Wagenaar-Bos IGA, Roem D, López-Lera A, López-Trascasa M, Tosi M, Drouet C. SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes. *Hum Mutat.* 2020; 41(1): 38-57. Article. IF: 4.878; Q2
 - Rodríguez-Martín E, Nieto-Ganan I, Hernández-Breijo B, Sobrino C, García-Hoz C, Bachiller J, Martínez-Feito A, Navarro-Compán V, Lapuente-Suanzes P, Bonilla G, Pascual-Salcedo D, Roy G, Jurado T, Nozal P, Vázquez-Díaz M, Balsa A, Villar LM, Plasencia-Rodríguez C. Blood lymphocyte subsets for early identification of non-remission to TNF inhibitors in rheumatoid arthritis. *Front Immunol.* 2020; 11: 1913. Article. IF: 7.561; Q1
 - Urban JG, Gurrado K, Rivas PCB, Abou Elrous D, Machain MZ, Gómez MR, Rodríguez JG, Plaza BV, Gregorio LY, Fernández EG, Martín CJ, Oliva MOL, García EG, Sánchez GL, Cornejo GC, Gutierrez RS, Santovena AZ, Hijosa MM, Cambor CF, del Castillo YM, Sisinni L, Sánchez DB, Pérez-Martínez A, Zapardiel ES, Granados EL, Villatoro JM, Zabala RH, Borobia AM, Frías J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? *Transpl Infect Dis.* 2020; 22(6): e13432. Article. IF: 2.228; Q4

Research projects

García-Giménez JL, Sánchez-Corral Gómez P. Validación de biomarcadores para

el diagnóstico y el pronóstico de la sepsis neonatal (ACCI2018-09). ISCIII. 2019-2021.

Management centre: CIBERER

López Lera A. Angioedema hereditario sin deficiencia de C1-Inhibidor: nuevas aproximaciones diagnósticas y pronósticas. Modelo para el estudio de FXII, una molécula pleiotrópica (ACCI2018-04). ISCIII. 2019-2021.

Management centre: CIBERER

López Trascasa M. Complementest. Déficits y alteraciones del sistema del complemento en patología humana. Secugen S. L. 2011-Ongoing.

Management centre: FIBHULP

Nozal Aranda P, Corvillo Rodríguez F. Detección y caracterización de autoanticuerpos en pacientes con lipodistrofia generalizada adquirida (síndrome de Lawrence). Asociación de Familiares y Afectados de Lipodistrofia (AELIP). 2019-2021.

Management centre: CIBERER

Sánchez-Corral Gómez P. Contrato garantía juvenil técnico laboratorio (PEJ-2017-TL/BMD-6873). CM. 2018-2020.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Contrato Miguel Servet Categoría A (CES07/030). CM. 2008-2025.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Contribución de variantes de las proteínas FHRS (factor H-Retald) del complemento en patología renal. Fundación SENEPRO. 2018-Ongoing.

Management centre: FIBHULP

Sánchez-Corral Gómez P. El sistema del complemento en salud y enfermedad (Complemento II-CM) (S2017/BMD-3673). CM. 2018-2021.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Nefropatías asociadas con desregulación del complemento: estudio de factores de riesgo y evolución mediante proteómica traslacional (PI16/00723). ISCIII. 2017-2020.

Management centre: FIBHULP

Sánchez-Corral Gómez P. Perfiles cuantitativos de las proteínas FH/FHRS del complemento como biomarcadores de predisposición y pronóstico en el síndrome hemolítico-urémico primario y secundario (PI19/00970). ISCIII. 2020-2022.

Management centre: FIBHULP

Cibers and Retics

Sánchez-Corral Gómez P. Networked Biomedical Research Center for Rare Diseases (CB06/07/1033). ISCIII. [31/12/2021]

Patents and trademarks

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

